Unilateral multicystic dysplastic kidney in infants exposed to antiepileptic drugs during pregnancy

被引:0
作者
Maurizio Carta
Marcello Cimador
Mario Giuffrè
Maria Sergio
Maria Rita Di Pace
Enrico De Grazia
Giovanni Corsello
机构
[1] Università di Palermo,UTIN e Pediatria
[2] Università di Palermo,Unità di Chirurgia Pediatrica, Dipartimento Materno Infantile
[3] Università di Palermo,Dipartimento Materno
来源
Pediatric Nephrology | 2007年 / 22卷
关键词
Multicystic dysplastic kidney; Antiepileptic drugs; Major congenital anomalies; Infant;
D O I
暂无
中图分类号
学科分类号
摘要
Prenatal exposure to antiepileptic drugs (AEDs) increases the risk of major congenital malformations (MCM) in the fetus. AED-related abnormalities include heart and neural tube defects, cleft palate, and urogenital abnormalities. Among the various congenital anomalies of the kidney and urinary tract (CAKUT), multicystic dysplastic kidney (MCDK) disease is one of the most severe expressions. Although prenatal ultrasound (US) examination has increased the prenatal diagnosis of MCDK, the pathogenesis is still unclear. We report on four cases of MCDK in infants of epileptic women treated with AEDs during pregnancy. From October 2003 to June 2006, we observed four infants with unilateral MCDK born to epileptic women. Three patients were considered to have typical features of multicystic dysplastic kidney, and one infant was operated because of a cystic pelvic mass in the absence of a kidney in the left flank. The macroscopic appearance of this mass showed an ectopic multicystic kidney confirmed by histological findings. All patients have been studied by US scans, voiding cystourethrogram (VCUG), and radionuclide screening isotope imaging. The prenatal exposure to AEDs increases the risk of major congenital malformations from the background risk of 1–2% to 4–9%. AEDs may determine a defect in apoptosis regulation that could lead to abnormal nephrogenesis, causing MCDK. Carbamazepine (CBZ) and phenobarbital (PHB) during pregnancy should be used at the lowest dosage compatible with maternal disease. The reduction, or even suspension, of drug dosage should be achieved from the periconceptional period to the first 8 weeks of gestation to avoid any interference with organogenesis.
引用
收藏
页码:1054 / 1057
页数:3
相关论文
共 101 条
[1]  
Holmes LB(2001)The teratogenicity of anticonvulsant drugs N Eng J Med 344 1132-1138
[2]  
Harvey EA(2004)Pregnancy in women who have epilepsy Neurol Clin 22 799-820
[3]  
Coull BA(2004)Malformation rates in children of women with untreated epilepsy; a meta-analysis Drug Saf 27 197-202
[4]  
Huntington KB(1999)Malformations in offspring of women with epilepsy: a prospective study Epilepsia 40 1231-1236
[5]  
Khoshbin S(2000)Population based, prospective study of the care of woman with epilepsy in pregnancy BMJ 321 674-675
[6]  
Hayes AM(2001)The use of anticonvulsants during pregnancy Semin Perinatol 25 153-158
[7]  
Ryan LM(1978)Seizures, anticonvulsants, and pregnancy Am J Dis Child 132 746-748
[8]  
Pennel PB(1999)Antiepileptic drug regimens and major congenital abnormalities in the offspring Ann Neurol 46 739-746
[9]  
Fried S(2004)Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepin and valproic acid: a nation-wide, population-based register study Acta Pediatr 93 174-176
[10]  
Kozer E(2002)The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures Reprod Toxicol 16 9-17